J&J pitch­es its S1P1 MS drug in­to the reg­u­la­to­ry ring as the com­pe­ti­tion heats up fast

The S1P1 ri­val­ry in the mul­ti­ple scle­ro­sis are­na is about to heat up sub­stan­tial­ly.

Six months af­ter beat­ing out Auba­gio in a head-to-head study, J&J has teed up its mar­ket­ing ap­pli­ca­tion for pones­i­mod. If ap­proved the drug, a big prize in their $30 bil­lion Acte­lion buy­out, will go up against No­var­tis’ ri­val Mayzent as well as ozan­i­mod from Bris­tol My­ers — which is fac­ing a loom­ing PDU­FA date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.